FY2025 EPS Estimates for Kodiak Sciences Lifted by Analyst

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for Kodiak Sciences in a report released on Thursday, January 22nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($4.29) for the year, up from their prior estimate of ($4.35). HC Wainwright has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.13) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($2.33) EPS and FY2029 earnings at ($0.57) EPS.

Several other research firms have also recently commented on KOD. Chardan Capital reiterated a “neutral” rating and set a $14.00 price target on shares of Kodiak Sciences in a report on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday. Wall Street Zen downgraded shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 11th. JPMorgan Chase & Co. raised Kodiak Sciences from a “neutral” rating to an “overweight” rating and increased their target price for the company from $15.00 to $24.00 in a report on Friday, October 24th. Finally, UBS Group assumed coverage on Kodiak Sciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $28.29.

Kodiak Sciences Stock Performance

KOD stock opened at $25.86 on Monday. The company’s 50 day moving average price is $25.40 and its 200 day moving average price is $16.62. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $31.18. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.28 and a beta of 2.67.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.09).

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker purchased 2,608,696 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $23.00 per share, for a total transaction of $60,000,008.00. Following the purchase, the director directly owned 18,358,772 shares of the company’s stock, valued at $422,251,756. The trade was a 16.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 45.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Kodiak Sciences

A number of institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. grew its position in Kodiak Sciences by 55.1% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company’s stock worth $7,668,000 after purchasing an additional 730,000 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Kodiak Sciences by 1.2% in the second quarter. Acadian Asset Management LLC now owns 1,969,876 shares of the company’s stock valued at $7,343,000 after buying an additional 23,742 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Kodiak Sciences by 7.0% during the third quarter. Vanguard Group Inc. now owns 1,950,292 shares of the company’s stock worth $31,926,000 after buying an additional 127,991 shares during the period. Boone Capital Management LLC purchased a new position in shares of Kodiak Sciences during the third quarter worth about $11,719,000. Finally, Nantahala Capital Management LLC grew its holdings in shares of Kodiak Sciences by 11.3% during the second quarter. Nantahala Capital Management LLC now owns 590,884 shares of the company’s stock worth $2,204,000 after buying an additional 60,171 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: HC Wainwright raised its Q4 2025 and FY2025 EPS estimates slightly (Q4 2025: from ($1.07) to ($1.02); FY2025: from ($4.35) to ($4.29)), and materially improved its FY2029 loss forecast (from ($0.82) to ($0.57)). These changes modestly tighten longer‑range expectations and could be seen as evidence of gradual improvement further out.
• Neutral Sentiment: Analysts published FY2030 forecasts for Kodiak that extend the modeling horizon but contain no immediate operational updates; long‑range projections often have limited short‑term trading impact. Read More.
• Negative Sentiment: HC Wainwright cut multiple near‑term estimates across 2026 and beyond: Q1–Q3 2026 EPS were lowered (Q1 to ($0.75) from ($0.68); Q2 to ($0.76) from ($0.70); Q3 to ($0.80) from ($0.73)); Q4 2026 was also trimmed to ($0.84). FY2026 was reduced to ($3.13) from ($2.88), and FY2027/FY2028 were also adjusted downward. The cluster of downward revisions increases uncertainty around near‑term cash burn and milestones, which is likely the main pressure on the stock today.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.